What Is Retatrutide?

Retatrutide is a 39 amino acid synthetic peptide, coded LY3437943 in development, that activates three receptors from one molecule: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. A fatty diacid side chain binds serum albumin, and published studies report a circulation half-life close to six days. The compound is still in phase 3 study, has no ARTG entry, and is supplied in Australia only as a research material for in-vitro work.

What Is a Retatrutide Molecule Made Of?

A retatrutide molecule is a single linear chain of 39 residues built on a GIP-like backbone, with several non-coded amino acids and one lipid modification. The molecular weight is roughly 4,731 Da. Three design choices define it.

• **Backbone:** the sequence borrows from GIP and adds features recognised by the GLP-1 and glucagon receptors, so one chain engages all three targets.
• **Protease resistance:** alpha-aminoisobutyric acid (Aib) and other non-natural residues replace positions that dipeptidyl peptidase-4 would otherwise cleave within minutes.
• **Lipidation:** a fatty diacid is attached through a hydrophilic linker to a lysine side chain. This is the element that ties the molecule to albumin.

In our catalogue it is listed under the metabolic research peptides range alongside single and dual agonists used as comparators.

What Receptors Does Retatrutide Target?

Retatrutide targets the GIP receptor, the GLP-1 receptor and the glucagon receptor, all class B G protein-coupled receptors that signal through cyclic AMP. The discovery paper in Cell Metabolism (2022) reported that the molecule was substantially more potent at the human GIP receptor than the endogenous hormone and less potent than native GLP-1 and native glucagon at their own receptors. That imbalance is deliberate: the design weights the GIP signal and keeps glucagon activity moderate.

Is Retatrutide a GLP-1 Agonist?

Retatrutide does activate the GLP-1 receptor, yet describing it only as a GLP-1 compound misses two thirds of its pharmacology. Semaglutide acts on the GLP-1 receptor alone and tirzepatide on the GIP and GLP-1 receptors. Retatrutide adds the glucagon receptor, so published papers class it as a triple agonist, sometimes written GGG agonist. Researchers use it to ask what a third receptor contributes when the first two are already engaged.

What Is the Half-Life of Retatrutide?

The half-life of retatrutide is about six days, as reported in the early clinical pharmacology published in Cell Metabolism in 2022. Native GIP and GLP-1 circulate for only a few minutes. The difference comes from the fatty diacid: once bound to albumin, the peptide is shielded from renal filtration and from peptidases, and it is released slowly from that reservoir. A six day circulation time is a property of the molecule in a living system. It is unrelated to the shelf life of a mixed vial held at 2 to 8 degrees C, which is a separate stability question covered in our note on reconstituted retatrutide stability.

What Is Another Name for Retatrutide?

Another name for retatrutide is LY3437943, the development code under which it was first described and under which most trial registrations list it. Retatrutide is the international nonproprietary name. It has no approved trade name in Australia, and laboratory documentation should record the generic name, the development code and the batch number printed on each vial.

Who Makes Retatrutide?

Retatrutide was developed by a pharmaceutical company that runs its clinical programme under the code LY3437943, and its developer sponsors the phase 3 trials now in progress. Research-grade material for laboratory use is made by solid-phase peptide synthesis, purified and lyophilised. We supply that research material: purity of every batch is measured by HPLC at 98% or higher, mass spectrometry confirms identity, and each lot ships with its own certificate of analysis.

What Is Retatrutide Used for in Laboratory Research?

What is retatrutide used for in the laboratory is a question of receptor pharmacology: it serves as a single-molecule probe of combined GIP, GLP-1 and glucagon receptor signalling. Typical in-vitro designs include cyclic AMP accumulation assays in cell lines expressing one receptor at a time, receptor internalisation studies, and side-by-side comparisons with semaglutide and tirzepatide to isolate the glucagon receptor contribution. Albumin binding assays and peptide stability studies in buffer are also common.

What Does the Published Research Record Show?

The published research record shows a steady progression from discovery through phase 2, with phase 3 now underway. The journals and years are the useful reference points for anyone building a literature review.

• **Discovery and first clinical pharmacology:** Cell Metabolism, 2022.
• **Phase 1b study:** The Lancet, 2022.
• **Phase 2 studies:** New England Journal of Medicine, 2023, and The Lancet, 2023.
• **Phase 2 liver fat substudy:** Nature Medicine, 2024.
• **Phase 3 programme:** multiple trials in progress.

Each paper is summarised with its design in the retatrutide study library. Because no phase 3 data have led to registration in Australia, the compound remains investigational here. Australian regulatory status is explained in our note on retatrutide availability and TGA status.

Which Retatrutide Vial Sizes Do We Stock?

Our retatrutide range covers four lyophilised vial strengths (10mg, 15mg, 20mg, 30mg), all from the same controlled supply and each carrying a label that states the compound, the milligram amount, the lot and the storage temperature. Our recommendation for a first study is the Retatrutide 10mg, 15mg, 20mg and 30mg vials page, where the 10mg vial suits method development and the larger vials lower the cost per milligram for longer series.

• The retatrutide starter kit bundles one vial with diluent and the consumables needed to prepare it.
• The prefilled retatrutide pen format is offered in 15mg, 20mg, 30mg and 70mg for laboratories that prefer a cartridge presentation.
• Value packs of three 10mg vials and two 30mg vials are listed on the product page.

For reconstitution volumes, see the retatrutide reconstitution chart. For receptor-by-receptor comparison with its predecessors, see retatrutide vs tirzepatide vs semaglutide. All material is sold strictly for in-vitro research, for purchasers 18 years or older, and it is not intended for use in humans or animals.

Questions about what is retatrutide

More reading

Retatrutide vs Semaglutide vs Tirzepatide: What Is the Difference?How Much Bacteriostatic Water to Mix with Retatrutide?When Will Retatrutide Be Available in Australia? Every guide on the research peptide blog

Sources